101 filings
Page 3 of 6
6-K
2947b349 wxoihgx
3 Apr 23
Consolidated Financial Statements
6:05am
6-K
firdvnkxyxy acdxky18
14 Mar 23
Current report (foreign)
9:08am
6-K
0zbpl3wxdjez9w
7 Feb 23
XORTX Provides Update on 2022 Achievements and 2023 Planned Milestones
7:00am
6-K
pn2k ksaiwy
1 Feb 23
XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease
7:00am
6-K
qhvvyxn whems
19 Jan 23
XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial
7:00am
6-K
0anymyqavoe nt
3 Jan 23
XORTX Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression
10:26am
6-K
v3wpu1
19 Dec 22
XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Study
8:12am
6-K
1o4src 2c
8 Dec 22
Independent Study Shows Moderate Dose Strength of XORLOâ„¢ Attenuates Kidney Expansion
7:00am
6-K
rwz5idy
28 Nov 22
XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study
7:00am
6-K
1fldfks4v0e9 t2
25 Nov 22
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
6:45pm
6-K
8vsg0 ufh90aw0aapza
16 Nov 22
XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer
7:29am
6-K
hrmj0
14 Nov 22
Condensed Interim Consolidated Financial Statements
1:04pm
6-K
9dg2p3
3 Nov 22
XORTX Presents New Proof of Concept Data at American Society of Nephrology
5:01pm
6-K
zlgcnp6b1q
3 Nov 22
XORTX Announces Participation at Upcoming Investor Conferences
10:52am
6-K
xjf23b5o83mmn1q5jb
26 Oct 22
XORTX Receives Further No Objection Letter from Health Canada
7:52am
6-K
20fulr9z
25 Oct 22
Current report (foreign)
7:12am
6-K
21ftnsoom6 obhs
7 Oct 22
XORTX Announces Closing of US$5 Million Public Offering
6:21pm
6-K
vbrec7 s4gbow
7 Oct 22
Current report (foreign)
4:30pm
6-K
n3fe5e ligm
6 Oct 22
A.G.P./Alliance Global Partners
4:47pm
6-K
rs70aoosr4 770
4 Oct 22
XORTX Announces US$5 Million Public Offering
9:05am